- * Male and female individuals 18 years of age and older at the time of enrollment who are mentally competent, willing and able to understand the nature and risks of the proposed study, and able to sign the consent form prior to study entry;
- * Individuals who are able to comply with all study procedures and requirements;
- * Healthy volunteers and volunteers specifically HIV positive, transplant recipients, cancer patients may be eligible;
- * Please contact the site for additional eligibility criteria.
Influenza, Human
Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Immunosuppressive Conditions *aH5N1:Monovalent H5N1 Influenza Vaccine
NCT02107807 | PHASE 3 | INTERVENTIONAL
Evaluate the safety, immune response and reactogenicity of aH5N1 vaccination in adult (18 through 60 years of age) and elderly (≥61 years of age) subjects with and without immunosuppressive conditions.
Trial Information
If interested, contact clinicaltrials@cslbehring.com for more information
CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy
, Novartis Investigational Site
Darlinghurst,New South Wales,Australia,2010
, Novartis Investigational Site
Darlinghurst,New South Wales,Australia,2010
, Novartis Investigational Site
Merewether,New South Wales,Australia,2291
, Novartis Investiagtional Site
Würzburg,Bayern,Germany,97070
, Novartis Investigational Site
Rostock,Mecklenburg-Vorpommern,Germany,18057
, Novartis Investigational Site
Magdeburg,Sachsen-Anhalt,Germany,39120
, Novartis Investigational Site
Hamburg,Germany,39120
, Novartis Investigational Site
Fossacesia,Chieti,Italy,66022
, Novartis Investigational Site
Lanciano,Chieti,Italy,66034
, Novartis Investigational Site
Monza,Milan,Italy,20052
, Novartis Investigational Site
Aviano,Padova,Italy,33080
, Novartis Investigational Site
San Daniele del Friuli,Udine,Italy,33038
, Novartis Investigational Site
Chieti,Italy,66013
, Novartis Investigational Site
Chieti,Italy,66013
, Novartis Investigational Site
Milan,Italy,20127
, Novartis Investigational Site
Milan,Italy,20157
, Novartis Investigational Site
Parma,Italy,43100
Study Eligibility Criteria
Additional Studies
Additional studies can be found at ClinicalTrials.gov